Live Chat ×
Skip to main content

Debate: Clearance (CL) vs. Elimination Rate Constant (ke)

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Nicholas HG Holford, MBChB, FRACP

    Dr. Holford is Professor of Clinical Pharmacology at the University of Auckland. His research interests include population PKPD analyses of clinical trials of drugs, PKPD in neonates and children and rational approaches to dose individualization. He has developed the use of disease progress models for understanding clinical pharmacology with an emphasis on the effects of drugs in Parkinson's Disease and predicting clinical outcome events through the use of biomarker driven hazard functions. He is past president of the Australia and New Zealand Society of Experimental and Clinical Phamacology and Toxicology in New Zealand and past president of the Population Analysis Group of Australia and New Zealand.

  • Roger Jelliffe MD, FCP, FAAPS

    Roger Jelliffe, an adult cardiologist, developed the first software, for individualizing drug dosage regimens, for digitalis, in 1967. He founded the USC Laboratory of Applied Pharmacokinetics and directed it until he retired and had recruited Dr. Michael Neely, who became director in 2013. The laboratory has developed what is now the USC Pmetrics software for population modeling and the Bestdose clinical software for individualizing drug dosage regimens specifically with maximum precision, including different Bayesian methods for managing individual patients in various clinical situations. The laboratory has contributed significantly to optimize therapy for cardiovascular, bacterial and fungal diseases, and transplants, and for acutely ill and unstable patients in the ICU.

April 13, 2017
Thu 12:30 PM EDT

Duration 1H 30M

This live web event has ended.